Phase 2Active, not recruitingAge-related condition
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.
- Sponsor
- Cognition Therapeutics (Industry)
- Enrollment
- 540 planned
- Conditions
- Early Alzheimer's Disease
- Interventions
- CT1812; Placebo
- Ages
- adults, older adults
- Registry
- NCT05531656
Full record on ClinicalTrials.gov
From the registry
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Primary outcomes
- Change from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale.
History
Primary completion expected
Last registry update
Started
Registered